Hacettepe University Faculty of Physical Therapy and Rehabilitation
Ankara, 06100, Turkey (Türkiye)
NCT Number: NCT05712798
The individuals with primary ciliary dyskinesia (PCD) have lower aerobic fitness and anaerobic performance than healthy individuals. Cardiopulmonary exercise test (CPET) provides an integrated assessment of integrative exercise responses involving the pulmonary, cardiovascular, hematopoietic, neuropsychological, and skeletal muscle systems that are not adequately reflected by measurement of the function of organ systems. Maximum oxygen consumption is measured by performing gas exchange analysis with CPET, offering an objective measure of cardiorespiratory fitness. The six-minute walk test (6MWT) and the shuttle walk test (SWT) are field tests that produce oxygen consumption results similar to those during CPET. There is a need to determine the physiological responses to CPET, SWT and 6MWT in individuals with PCD. Additionally, the physiological responses of individuals with PCD to different exercise tests will be compared with the responses of healthy individuals. Low aerobic capacity in individuals with PCD may affect the physical, emotional, and social lives of individuals. This influence may cause a decrease in the quality of life of individuals with PCD. The relationship between exercise capacity and quality of life in individuals with PSD will be investigated with this study.
Looking for future studies?
Notify Me8 year–18 year
All sexes
Observational
Ankara, 06100, Turkey (Türkiye)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The healthy group will be composed of individuals who do not have any known disease and volunteer to participate in the study. For healthy individuals, volunteers from acquaintances and/or relatives of the researchers will be included in the study.
Exclusion criteria
No intervention
Time frame: up to 3 weeks
Shuttle walk test distance will be determined using shuttle walk test
Time frame: 1st day
Quality of life score will be determined using multidimensional measure to assess health-related quality of life in primary ciliary dyskinesia (QoL-PCD).
Time frame: up to 3 weeks
Maximal oxygen uptake will be determined using cardiopulmonary exercise test.
Time frame: up to 3 weeks
6 minute walk test distance will be determined using 6 minute walk test
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced vital capacity will be recorded.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second will be recorded.
Time frame: 1st day
Maximal inspiratory pressure will be measured using a mouthpiece device.
Time frame: 1st day
Maximal expiratory pressure will be measured using a mouthpiece device.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded.
Time frame: 1stday
Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded.
Hacettepe University
Other
Physiological Responses to Exercise Tests in Primary Ciliary Dyskinesia Compared With Healthy Children and Investigation of the Relationship Between Exercise Capacity and Quality of Life in Primary Ciliary Dyskinesia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00368446
Abnormalities, Multiple, Actinomycetales Infections
Bethesda, Maryland, United States
View Trial DetailsNCT05685186
Abnormalities, Multiple, Bronchial Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05161858
Abnormalities, Multiple, Bronchial Diseases
Palo Alto, California, United States
View Trial DetailsNCT06600425
Abnormalities, Multiple, Bronchial Diseases
London, United Kingdom
View Trial Details